Study: A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer
Phase III
· Site: SITE015 (POL) (Dr. Ito)
· consented 2023-03-02
Adverse events
5
Serious AEs
1
Open data queries
0
Luna dropout signal
–
Adverse events
moderate
assessed
2026-08-18
Grade 2 Decreased appetite — outcome: RECOVERED/RESOLVED; onset 2023-03-23 (study day 9); relationship: not assessed
mild
assessed
2026-08-18
Grade 1 Asthenia — outcome: RECOVERED/RESOLVED; onset 2023-05-21 (study day 68); relationship: not assessed
severe
assessed
2026-08-18
Grade 3 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2023-05-22 (study day 69); relationship: Y
severe
serious
assessed
2026-08-18
Grade 3 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2023-05-31 (study day 78); relationship: not assessed; serious criteria: hospitalization
moderate
assessed
2026-08-18
Grade 2 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2023-06-03 (study day 81); relationship: not assessed
Data queries
No data queries.
☾ Luna engagement
This participant doesn't use Luna.